Navigation Links
New treatment approach promising for lymphoma patients in the developing world
Date:7/6/2008

Preliminary results suggest that patients with aggressive non-Hodgkin's lymphoma in the developing world might benefit from a modified chemotherapy regimen, researchers say.

At the ESMO Conference Lugano (ECLU) organized by the European Society for Medical Oncology, a group headed by Prof. Hamdy Azim from Cairo University reports that giving these patients chemotherapy every 2 weeks, rather than every 3 weeks as usual, improved treatment outcomes.

The standard regimen in this case is called CHOP (chemotherapy regime), which is given every 3 weeks. In the developed world, CHOP is administered in combination with an antibody therapy called rituximab.

But many patients in developing countries, including Egypt where this study was conducted, cannot afford this treatment, so they are offered CHOP alone.

"We hypothesized that if CHOP or a CHOP-like regimen was given every two weeks instead of three, a superior outcome could be achieved," says Dr. Hatem A. Azim Jr, who presented these results at ECLU.

To see if this was the case, they analyzed five trials that compared CHOP to regimens given every two weeks. Using two statistical analyses, they showed that regimens every two weeks had superior response rate, disease-free and overall survival; however in one method, the response rate analysis did not reach statistical significance.

"We believe that this work could provide good evidence to support the use of the 2-weekly regimen," Dr. Azim Jr said. One issue that remains to be assessed is how well patients tolerate the more intense treatment, he noted.

"Patients on the 2-weekly regimens have to receive injections with 'growth factors' to ensure that severe toxicities to the white blood cells do not occur," he said. "Even so, the cost of these injections per cycle is much lower than that of rituximab. The preliminary results are encouraging in providing patients who cannot afford the cost of rituximab, a better alternative than CHOP."


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Treatment delays result in poor outcomes for men with breast cancer
2. Counting tumor cells in blood predicts treatment benefit in prostate cancer
3. Stroke study reveals key target for improving treatment and suggests that Gleevec may help
4. Hypertension treatment effective in reversing vascular damage
5. Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment
6. Source of drug-tolerant tuberculosis possibly behind TB relapses, intensity of treatment
7. Novel therapeutic strategy for colon cancer treatment
8. New ballast treatment could protect Great Lakes fish
9. Quest for better treatment for effects of menopause
10. Sugar linkage could lead to better treatment for autoimmune diseases
11. Glypican-3 gene function in regulating body size helps inform novel cancer treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
(Date:2/1/2016)...  Today, the first day of American Heart Month, ... a first of its kind workplace health solution that ... the first application of Watson ... and Welltok will create a new offering that combines ... delivered on Welltok,s health optimization platform. The effort is ...
(Date:1/25/2016)... 2016  Glencoe Software, the world-leading supplier of image ... will provide the data management solution OMERO Plus for ... Photo - ... Phenotypic analysis measures the characteristics and behavior ... between states such as health and disease, the presence ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... Feb. 5, 2016 Australian-US drug discovery and development ... the appointment of a new Chairman, Mr John O,Connor ... effective immediately. James Garner , has also ... and former Acting CEO, Mr Iain Ross , will ... --> James Garner , has also been formally ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Bloomsburg University’s Digital Forensics Club, takes place February 5-6 at the University’s ... 20+ speakers and activities such as workshops and competitions for ample networking, ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016 ContraVir ... focused on the development and commercialization of targeted antiviral ... CEO & Investor Conference 2016, to be held February ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... on February 10-11, 2016. James Sapirstein , ...
(Date:2/4/2016)... ... ... Many of the engineers at FireflySci, Inc. have been manufacturing quartz and ... other cuvette manufacturers is their supercharged customer service and their extensive database of glass ... flow of inside information, they have recently revamped their manufacturing techniques to reduce lead ...
Breaking Biology Technology: